Treating An Elderly Woman with Chronic Lymphocytic Leukemia

Video

Treating An Elderly Woman with Chronic Lymphocytic Leukemia

An Elderly Woman With CLL

  • A 78-year—old female presented with symptoms of fatigue and loss of appetite for the past six months
  • PMH: recurrent bronchitis during past 12 months, treated with antibiotics
  • PE: vital signs WNL, right cervical lymphadenopathy, spleen palpable 5 cm below costal margin, otherwise well-appearing
  • Laboratory findings:
    • WBC, 53,000; 76% lymphocytes
    • Hb; 10.4 g/dL
    • Platelets; 150 X 109/L
    • ANC; 180/mm3
  • Flow cytometry; CD5+, CD19+, CD23+
  • Cytogenetics, FISH: trisomy 12; IgVH mutated
  • β2M, 3.6 mg/L
  • BM biopsy; diffuse infiltration by CLL
  • Diagnosis; chronic lymphocytic leukemia
  • The patient was treated with ibrutinib and achieved a complete response to therapy after 4 months
Recent Videos
Related Content
FDA Updates Fludarabine Labeling Under Project Renewal Initiative

FDA Updates Fludarabine Labeling Under Project Renewal Initiative

Jordyn Sava
November 20th 2024
Article

The FDA updated the fludarabine phosphate injection labeling under Project Renewal, clarifying the dosage for combination therapy and streamlining safety warnings.

Read More

Understanding the Role of Zanubrutinib for the Treatment of CLL

Understanding the Role of Zanubrutinib for the Treatment of CLL

Rohit Gosain, MD;Rahul Gosain, MD
April 23rd 2024
Podcast

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Listen

Exploring New Therapies and Sequencing in Relapsed CLL

Exploring New Therapies and Sequencing in Relapsed CLL

Ariana Pelosci
November 14th 2024
Article

Nicole Lamanna, MD, discussed some of the ongoing clinical trials evaluating new therapies for patients with chronic lymphocytic leukemia.

Read More

Exciting Activity in Chronic Lymphocytic Leukemia

Exciting Activity in Chronic Lymphocytic Leukemia

Nichole Tucker;Cyrus M. Khan, MD
May 31st 2023
Podcast

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Listen

Advancements in CLL: CAR T, BTK Inhibitors and Personalized Medicine

Advancements in CLL: CAR T, BTK Inhibitors and Personalized Medicine

Jordyn Sava
November 13th 2024
Article

Cyrus M. Khan, MD, discussed recent advancements in CLL treatment, particularly the shift to nonchemotherapy options and the availability of CAR T-cell therapy.

Read More

Nivolumab-Chemotherapy Combo Boosts PFS in cHL, Poised for Standard Use

Nivolumab-Chemotherapy Combo Boosts PFS in cHL, Poised for Standard Use

Morgan Bayer
November 12th 2024
Article

The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, particularly benefiting patients 60 and older.

Read More